Maximum tolerated dose evaluation of the AMPA modulator Org 26576 in healthy volunteers and depressed patients: a summary and method analysis of bridging research in support of phase II dose selection.

Saved in:
Bibliographic Details
Title: Maximum tolerated dose evaluation of the AMPA modulator Org 26576 in healthy volunteers and depressed patients: a summary and method analysis of bridging research in support of phase II dose selection.
Authors: Nations KR; Merck Sharp Dohme Corp., Whitehouse Station, NJ, USA., Bursi R, Dogterom P, Ereshefsky L, Gertsik L, Mant T, Schipper J
Source: Drugs in R&D [Drugs R D] 2012 Sep 01; Vol. 12 (3), pp. 127-39.
Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
Journal Info: Publisher: Adis, Springer International Country of Publication: New Zealand NLM ID: 100883647 Publication Model: Print Cited Medium: Internet ISSN: 1179-6901 (Electronic) Linking ISSN: 11745886 NLM ISO Abbreviation: Drugs R D Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1179-6901
DOI:10.2165/11634360-000000000-00000